Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Roche and Genentech prepare prodrugs of fibrinogen antagonist

Sep. 6, 1996

Thalidomide derivatives as leads for septic shock therapy

Sep. 6, 1996

CGS-28106 for hypertension and congestive heart failure

Sep. 6, 1996

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

Sep. 6, 1996

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

Sep. 6, 1996

Mechanism-based enzyme inhibitor may serve as a lead for new anticonvulsants

Sep. 6, 1996

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

Abbott evaluating clitocine analogues

Sep. 6, 1996

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...